Last reviewed · How we verify
Ketamine Intravenous Infusion
At a glance
| Generic name | Ketamine Intravenous Infusion |
|---|---|
| Sponsor | NeuroRx, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.
- Ketamine + Cognitive Training for Suicidality in the Medical Setting (PHASE4)
- Ketamine for Veterans With Parkinson's Disease (PHASE2)
- Ketamine Treatment of Youth Suicide Attempters (PHASE3)
- InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression (PHASE3)
- Postoperative Pain Monitoring With ANI in Lumbar Spine Surgery (NA)
- Small Study Comparing Two Pain Medicines in Teenagers for Pain Control After Scoliosis Corrective Surgery. (NA)
- Pilot Study of RR-HNK in OCD (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketamine Intravenous Infusion CI brief — competitive landscape report
- Ketamine Intravenous Infusion updates RSS · CI watch RSS
- NeuroRx, Inc. portfolio CI